|
ATPBD4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.45570033594345E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.89879999688148E-08 |
| Normal-vs-Stage2 |
4.31020000000171E-05 |
| Normal-vs-Stage3 |
2.68750000032014E-09 |
| Normal-vs-Stage4 |
7.4852002374115E-10 |
| Stage1-vs-Stage2 |
6.586200E-01 |
| Stage1-vs-Stage3 |
4.066300E-02 |
| Stage1-vs-Stage4 |
1.328430E-02 |
| Stage2-vs-Stage3 |
3.513600E-01 |
| Stage2-vs-Stage4 |
1.245960E-01 |
| Stage3-vs-Stage4 |
4.197400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.50649953517745E-10 |
| Normal-vs-AfricanAmerican |
1.031490E-04 |
| Normal-vs-Asian |
4.10690000007818E-07 |
| Caucasian-vs-AfricanAmerican |
8.273200E-01 |
| Caucasian-vs-Asian |
6.516400E-01 |
| AfricanAmerican-vs-Asian |
9.182600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.51199996967222E-09 |
| Normal-vs-Female |
6.17240003553121E-09 |
| Male-vs-Female |
1.649400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.83850000019015E-07 |
| Normal-vs-Age(41-60Yrs) |
6.46150000171986E-09 |
| Normal-vs-Age(61-80Yrs) |
3.00419999987867E-09 |
| Normal-vs-Age(81-100Yrs) |
5.5703000000018E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.637600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.323580E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.052200E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.303000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.062960E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.686750E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.900600E-01 |
| Classical-VS-Follicular |
5.256000E-01 |
| Classical-VS-Other |
7.498000E-01 |
| Classical-VS-Normal |
5.7033000544493E-09 |
| Tall-VS-Follicular |
2.809000E-01 |
| Tall-VS-Other |
4.137000E-01 |
| Tall-VS-Normal |
4.18239999999681E-06 |
| Follicular-VS-Other |
9.293800E-01 |
| Follicular-VS-Normal |
4.26040000000016E-05 |
| Other-VS-Normal |
5.281600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.34940000787276E-09 |
| Normal-vs-N1 |
4.36410000026477E-07 |
| N0-vs-N1 |
8.460600E-01 |
|
|
